Germline Profiling and Molecular Characterization of Early Onset Metastatic Colorectal Cancer

Ting Xu(Beijing Tian Tan Hospital), Xicheng Wang(Shanghai East Hospital), Changsong Qi(Peking University), Jing Zhang(Sichuan Agricultural University), Zhenghang Wang(Peking University), Ting Hou(Burning Rock Biotech (China)), Yanyan Li(Guangdong Academy of Medical Sciences), Dan Liu(Machine Intelligence Research Institute), Lu Zhang(Burning Rock Biotech (China)), Jian Li(National Center on Birth Defects and Developmental Disabilities), Hao Liu(Chinese Academy of Medical Sciences & Peking Union Medical College), Lin Shen(Hangzhou Normal University), Yinjie Zhang(Shanxi University), Congcong Ji(Peking University), Xuan Lin(Beijing Technology and Business University), Han Han‐Zhang(Burning Rock Biotech (China))
Frontiers in Oncology
October 19, 2020
10.3389/fonc.2020.568911
Cited by 47

Related Papers

Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
|Nature|2021|687
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial
|BMJ|2022|494
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
|Annals of Oncology|2019|475
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
|The Lancet|2023|461